Psychedelic mental health treatment developer

Been researching companies working on new approaches for mental health treatment using psychedelic compounds.

One company I looked at is advancing deuterated versions of psilocybin and DMT. Their lead program is currently in Phase 3 for Major Depressive Disorder, with another in Phase 2 for anxiety.

Market cap is in the mid $200M range, with several clinical catalysts expected over the next 12-18 months.

This space is still high risk and early stage. Clinical results, regulation, and execution are all critical factors.

Just sharing for discussion. Anyone else looking into psychedelic or mental health biotech?

(Not financial advice. DYOR.)